Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Tvardi Therapeutics ( (TVRD) ) is now available.
On May 27, 2025, Tvardi Therapeutics announced the completion of enrollment in its Phase 2 clinical trial for TTI-101, a treatment for idiopathic pulmonary fibrosis (IPF). This milestone marks a significant step in addressing IPF, a chronic lung disease with limited treatment options. The trial aims to evaluate the safety and efficacy of TTI-101, an oral STAT3 inhibitor, with topline data expected in the fourth quarter of 2025.
The most recent analyst rating on (TVRD) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tvardi Therapeutics stock, see the TVRD Stock Forecast page.
Spark’s Take on TVRD Stock
According to Spark, TipRanks’ AI Analyst, TVRD is a Neutral.
Cara Therapeutics’ stock is currently buoyed by strong technical momentum, with prices significantly above key moving averages and positive market indicators. However, significant financial challenges, including negative profitability and cash flow issues, weigh heavily on the stock’s long-term outlook. The lack of profitability is reflected in a negative P/E ratio, making valuation difficult and risky. Investors should be cautious of the high financial risks despite the current positive technical trends.
To see Spark’s full report on TVRD stock, click here.
More about Tvardi Therapeutics
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet needs. The company is conducting Phase 2 clinical trials for idiopathic pulmonary fibrosis and hepatocellular carcinoma.
Average Trading Volume: 23,155
Technical Sentiment Signal: Hold
Current Market Cap: $272.3M
Find detailed analytics on TVRD stock on TipRanks’ Stock Analysis page.